You are here

Novartis sees profit margin hike as it revamps drug portfolio

Novartis is in a strong position relative to its peers thanks to recent advances with new drugs, including a widely anticipated heart failure medicine and a recently launched psoriasis injection.

PHOTO: BLOOMBERG

Zurich

NOVARTIS AG said on Thursday it expects to increase its profit margin this year as it restructures its drug portfolio and cuts costs, as well as generate cash for a higher dividend and smaller, strategic acquisitions.